Trading Signals: ALLO Stock Price Prediction and Forecast (Wed. Oct. 10, 2018 - Wed. Sep. 27, 2023)(Allogene Therapeutics, Inc.)
| ALLO latest price $23.4000 (-1.68%) ($23.0000 - $24.4000) on Fri. Oct. 19, 2018. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 14.46% (three month average) | | RSI | 50 | | Latest Price | $23.4000(-1.68%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | ALLO declines -2.7% a day on average for past five trading days. | | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | | Correlated ETFs | Broad market will support ALLO advance at 0% a week (0% probability)
XBI(51%) ARKG(50%) IBB(44%) ARKK(43%) IWO(41%) | | Factors Impacting ALLO price | ALLO will decline at least -7.23% in a week (0% probabilities).
VXX(-9%) UUP(-9%) VIXM(-7%) TLT(-5%) DIA(-5%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -7.23% (StdDev 14.46%) | | Hourly BBV | 0 () | | Intraday Trend | -2% | | | | | |
|
| 5 Day Moving Average | $25(-6.4%) | | 10 Day Moving Average | $0(INF%) | | 20 Day Moving Average | $0(INF%) | | To recent high | -13.2% | | To recent low | 30% | | Market Cap | $3.258b | | | | | | |
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA. |